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Stereoselective synthesis of fluorinated galactopyranosides as 
potential molecular probes on galactophilic proteins: assessment 
of monofluorogalactosides-LecA interactions 
Vincent Denavit,[a] Danny Lainé,[a] Chahrazed Bouzriba,[b, c] Elena Shanina,[d] Émilie Gillon,[e] Sébastien 
Fortin,[b, c] Christoph Rademacher,[d] Anne Imberty,[e] and Denis Giguère*[a] 
Abstract: The replacement of hydroxyl groups by fluorine atoms on 
hexopyranoside scaffolds may allow access to invaluable tools to 
study various biochemical processes. As part of ongoing activities 
toward the preparation of fluorinated carbohydrates, a systematic 
investigation involving the synthesis and biological evaluations of a 
series of mono- and polyfluorinated galactopyranosides is described. 
The preparation of all the monofluorogalactopyranosides, one 
trifluorinated galactopyranoside, and the tetrafluorinated 
galactopyranoside was achieved using a Chiron approach. The 
synthetic challenge they present combined with the scarcity of some 
of these compounds prompted us to evaluate their biological profile. 
Firstly, our fluorinated compounds were investigated as 
antiproliferative agents using normal human and mouse cells and 
compared with cancerous cells. Most of the fluorinated compounds 
showed no antiproliferative activity. Secondly, we used these 
carbohydrate probes as potential inhibitors for galactophilic lectins. 
We performed the first TROSY NMR, chemical shift perturbations of 
the backbone resonances of LecA, a virulence factor from 
Pseudomonas aeruginosa. Moreover, taking advantage of the fluorine 
atom, we achieved the direct detection of the 19F NMR resonance of 
the monofluorogalactopyranosides in presence and absence of LecA 
to monitor ligand binding. Lastly, these results were corroborated with 
the binding potency of the monofluorinated galactopyranoside 
derivatives by isothermal titration calorimetry experiments. Analogs 
with fluorine atoms at C-3 and C-4 have weaker affinities with LecA 
as compared to compounds with fluorine atom at C-2 and C-6. This 
research focused on the chemical synthesis of “drug-like” low-
molecular weight inhibitors that circumvent drawbacks typically 
associated with natural oligosaccharides. 
Introduction 
The most widespread application of fluorinated 
carbohydrates is as radiopharmaceuticals for cancer imaging 
technique.[1] Fluorinated carbohydrates are also invaluable tools 
as mechanistic probes to study lectin-carbohydrate interactions 
and to decipher the mechanisms of glycosidases.[2] To that end, 
deoxyfluoro sugars provide useful insights into the role of 
hydrogen bonding interactions in order to identify the key active 
site of enzyme-substrate interactions. 
Lectins, carbohydrate binding proteins, are found in all 
organisms from animals and plants, to bacteria and viruses.[3] 
Lectins are involved in various biological processes, and their 
properties are in relation with their carbohydrate binding 
domain.[4] Hence, it is crucial to elucidate and understand the 
sugar binding properties of lectins.[5 ] Among them, galactose-
specific lectins are of high interest as they bind for example to β-
galactose present on branches of N-linked glycans, or to α-
galactose epitopes of some human and non-human blood 
groups.[ 6 , 7 ] Galactose-specific lectins of therapeutical interest 
include for example LecA (PA-IL lectin from the pathogenic 
Pseudomonas aeruginosa), galectins, asialoglycoprotein 
receptor, and macrophage galactose-binding lectin. Intense 
investigations have been devoted to the understanding of these 
lectins ability to regulate numerous biological processes. Since 
thorough understanding of biochemical pathways is hampered by 
the natural complexity of carbohydrates, chemical or chemo-
enzymatic synthesis of glycomimetics ligands is likely to remain a 
valuable option in glycoscience. Therefore, there is a major need 
to develop new tools that target galactoside-specific lectins in 
order to decipher their binding characteristics. 
The carbohydrate binding capability of numerous lectins has 
been demonstrated by determining their ability to bind glycan 
arrays and by inhibiting their interaction with glycoconjugates or 
glycomimetics.[8]  This  allows  insight  into  the  nature  of  the 
hydrogen bonding involved between the hydroxyl groups of 
carbohydrates and the binding sites of the proteins. The 
monosaccharides used in these studies generally include fluoro-, 
deoxy-, and thio-hexoses, along with uronic acids and alditols.[9] 
The major drawbacks to use such diverse glycomimetic libraries 
are their poor synthetic availability Consequently, the synthesis of 
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fluoro-, deoxy-, and thio-glycosides is of high interest. In this 
context, we wish to replace the carbohydrate hydroxyl groups with 
fluorine atoms to generate new fluorine-substituted glycoside 
analogs.[10] The rationale to synthesize such compounds emerges 
from the likenesses between hydroxyl group and fluorine atom in 
regard to polarity and isosteric relationships.[11] Also, the loss of 
hydrogen donating capacity for the fluorine atom and the high C−F 
bond energy render them resistant to rapid in vivo degradation.[12] 
Finally, addition of a fluorine group on a hydroxypyranose core 
can modulate the lipophilicity, which in turn can increase cell 
permeability.[ 13 ]  Definitely,  fluorinated  carbohydrates  could 
represent more “drug-like” tools that circumvent drawbacks 
typically associated with natural oligosaccharides, such as low 
affinity, limited metabolic stability, and high polarity leading to low 
bioavailability. 
As part of our ongoing program related to the synthesis of 
fluorinated carbohydrates,[14] our attention was turned toward the 
preparation of monofluorogalactopyranosides 1−4, along with the 
tetrafluorinated galactopyranoside congener 6 (Figure 1). On our 
way to prepare the polyfluoro derivative, we were also able to 
access trifluorinated galactopyranoside 5. Heavily fluorinated 
hexopyranosides (replacement of hydroxyl groups by fluorine 
atoms) are particularly interesting because of the synthetic 
challenge they present. We developed convenient synthetic 
methodologies for further biological investigations. In the 
expectation of increasing the molecular diversity of our library, two 
aglycones were installed at the anomeric position, a β-O-benzoic 
acid and a β-S-(2-naphthyl). This choice is no coincidence since 
some galactoside-specific lectins are known to bind such 
structural motifs.[15]  
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Figure 1. Mono- and polyfluorinated galactopyranosides prepared in this work. 
In the context of this study, it is important to point out that 
heavily fluorinated carbohydrates have been only used in kinetic 
studies,[16] to improve protein-carbohydrate interactions,[17] in the 
development of chemically modified analogs with improved 
antigenicity,[18] and have been evaluated for their ability to cross 
erythrocyte  membranes.[ 19 ]  The  interesting  properties  of 
polyfluorinated carbohydrates can partly be explained by 
desolvation effect, together with attractive dipolar interactions 
mediated by polar C−F bonds.[20] Herein, we present the first 
library and biological investigation of synthetic monofluorinated 
galactopyranosides. To the best of our knowledge, only one report 
described the hydrolysis of a series of fluorogalactopyranoside.[21] 
However, the synthetic preparation of these compounds was not 
described. Here, we disclosed the first antiproliferative screening 
of mono- and polyfluorinated galactopyranosides on human 
HaCat primary epidermal keratinocyte, human HDFn neonatal 
dermal fibroblast and mouse 3T3 embryonic fibroblast normal 
cells. These results were compared with human HT-29 colon 
adenocarcinoma and human M21 skin melanoma cancer cells. 
Also, our synthetic library could be useful as stable molecular 
probes with galactophilic lectins. This is exemplified by the first 
TROSY NMR monitoring chemical shift perturbation of LecA from 
the virulence factor Pseudomonas aeruginosa. Moreover, taking 
advantage of the properties of fluorine atom, the direct detection 
of the 19F NMR resonance of monofluorogalactopyranosides were 
performed on LecA to identify chemical shift changes of the 
ligands as well. Finally, these results were corroborated by the 
binding potency of the monofluorinated galactopyranoside 
derivatives by isothermal titration calorimetry. 
Results and Discussion 
Our synthetic endeavours started with the preparation of 2-
fluorogalactopyranosides. Compound such as 2F-glycosides are 
important tools used as specific mechanism-based glycosidase 
inhibitors.[16a, 22 ]  The  synthesis  of  2-deoxy-2-fluoro-
galactopyranoside derivatives is summarized in Scheme 1. Thus, 
acetylated galactoside 7 was transformed in two steps into known 
2,3,6-tri-O-D-galactal 8 in 91% yield. Treatment of compound 8 
with Selectfluor® on large scale exclusively led to 2-deoxy-2-
fluoro-D-galactopynoside 9 after O-acetyl protection of the 
anomeric position (α/β = 1.5:1).[23] Stereoselective installation of 
the anomeric aglycone proceeded through the α-galactosyl 
bromide 10. The crude bromide product underwent a phase 
transfer catalyzed nucleophilic displacement with methyl 4-
hydroxybenzoate or 2-naphthalenethiol, leading to derivative 11 
(63% yield over 2 steps) and 12 (55% yield over 2 steps) 
respectively. The β configurations were determined by direct NMR 
coupling of the anomeric proton with the H-2 proton, and the 
fluorine at C-2 (1H NMR (500 MHz)  5.23 (dd, 3JH1-H2 = 7.4 Hz, 
3JH1-F2 = 3.8 Hz) for 11 and 4.82 (dd, 3JH1-H2 = 9.6 Hz, 3JH1-F2 = 2.8 
Hz, 1H, H1) for 12). This methodology will be applied for the 
determination of the anomeric configuration of all the 
galactopyranoside derivatives prepared in this study.[24] 
Our next challenge involved the preparation of 3-deoxy-3-
fluorogalactopyranoside derivatives, which was based on our 
previously described method and summarized in Scheme 2.[14b] 
Briefly,  Cerny’s  epoxide  13[25]  was  treated  with  potassium 
hydrogen fluoride in ethylene glycol at 200 °C for 5 hours and 
yielded the desired 3-deoxy-3-fluoroglucopyranose 14 in 65% 
yield as the sole isomer. With the required 3-deoxy-3-fluoro 
derivative in hand, the next task involves inversion of 
configuration at C-4. Thus, benzoylation of the free hydroxyl group 
was followed by deprotection of the 4-O-benzyl group using TiCl4. 
Then, compound 15 was subjected to a Lattrell-Dax epimerization 
on gram scale through formation of triflate 16.[ 26 ] The crude 
mixture was treated with KNO2 in DMF and generated the desired 
1,6-anhydro-β-D-galactopyranose derivative 17 in 72% yield over 
2 steps. Acetolysis using a mixture of H2SO4 and Ac2O allowed 
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Scheme 1. Synthesis of 2-deoxy-2-fluoro-galactopyranosides 11 and 12. a) 
HBr/AcOH, CH2Cl2, rt, 2 h; b) Zinc (7.5 equiv), NH4Cl (7.5 equiv), CH3CN, 60 °C, 
45 min, 91% over 2 steps; c) Selectfluor® (1.2 equiv), CH3NO2/H2O (5:1), rt, 18 
h; d) Ac2O/pyridine (1:5), rt, 20 h, 64% over 2 steps; e) HBr/AcOH, CH2Cl2, rt, 
42 h; f) methyl 4-hydroxybenzoate (3.0 equiv), TBAHS (1.0 equiv), AcOEt/1M 
Na2CO3 (1:1), rt, 18 h, 63% over 2 steps; g) 2-thionaphthyl (3.0 equiv), TBAHS 
(1.0 equiv.), AcOEt/1M Na2CO3 (1:1), rt, 18 h, 55% over 2 steps. AcOH = acetic 
acid, Ac2O = acetic anhydride, Selectfluor® = 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate); TBAHS = 
tetrabutylammonium hydrogen sulfate. 
the generation of protected 3-deoxy-3-fluoro-D-galactopyranose 
18 in 58% yield (α/β = 3:1). The stereoselective functionalization 
of the anomeric position was easily achieved as described above. 
Thus, the mixture HBr/AcOH generated bromide 19, which was 
subsequently subjected to the phase transfer catalyzed reactions. 
Methyl 4-hydroxybenzoate 20 and 2-naphthalenethiol 21 were 
isolated in 63% and 67% yields, respectively over 2 steps. 
The syntheses of 4-deoxy-4-fluoro-galactopyranoside 
derivatives were initiated by the use of known 4-O-p-
toluenesulfonyl 22 (Scheme 3).[ 27 ] Protection of the residual 
hydroxyl group allowed the preparation of compound 23 in high 
yield and the latter was subjected to nucleophilic fluorination using 
TBAF in boiling THF. Compound 24 was isolated together with an 
unidentifiable impurity, consequently it was subjected to the next 
reaction. The mixture was directly subjected to acetolysis under 
acidic condition and the concomitant removal of the MOM 
protecting group proceeded as expected, generating intermediate 
25 in 52% yield over 2 steps (α/β = 3:1).[16c] Finally, the anomeric 
groups were installed using the strategy mentioned above, 
allowing the isolation of products 27 and 28 via bromide 
intermediate 26. 
The easiest fluorinated analog to prepare was undoubtedly 
the 6-deoxy-6-fluoro-galactopyranose. The synthetic route was 
straightforward and initiated with 1,2:3,4-di-O-isopropylidene-α-D-
galactopyranose 29 as inexpensive starting material (Scheme 4). 
Fluoro derivative 30 was isolated in 87% yield using Me-DAST 
with microwave irradiation (80 °C) for 1 hour. This method 
provided higher yield as compared to conventional heating. [14b] 
Next, isopropylidene hydrolysis was followed by acetyl protection 
allowing the preparation of anomeric mixture of 6-deoxy-6-fluoro-
galactopyranose 31. The latter was subjected to acidic conditions 
followed by phase transfer catalyzed reactions. Product 33 was 
isolated in 36% yield over 4 steps (78% per step) and product 34 
was isolated in 49% yield over 4 steps (83% per step). 
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Scheme 2. Synthesis of 3-deoxy-3-fluoro-galactopyranosides 20 and 21. a) 
KHF2 (6.1 equiv), ethylene glycol, 200 °C, 5 h, 65%; b) BzCl (3.0 equiv), pyridine, 
CH2Cl2, rt, 1 h, 81%; c) TiCl4 (1.1 equiv), CH2Cl2, 0 °C, 1 h, 82%; d) Tf2O (2.3 
equiv), pyridine, CH2Cl2, 0 °C to rt, 0.5 h; e) KNO2 (3.0 equiv), DMF, rt, 24 h, 
72% over 2 steps; f) H2SO4 (10.0 equiv), Ac2O (30.0 equiv), rt, 18 h, then NaOAc 
(20.0 equiv), rt, 0.3 h, 58% (α/β = 3:1); g) HBr/AcOH, CH2Cl2, 0 °C to rt, 2 h; h) 
methyl 4-hydroxybenzoate (3.0 equiv), TBAHS (1.0 equiv), AcOEt/1M Na2CO3 
(1:1), rt, 18 h, 63% over 2 steps; i) 2-thionaphthyl (3.0 equiv), TBAHS (1.0 equiv), 
AcOEt/1M Na2CO3 (1:1), rt, 18 h, 67% over 2 steps. Ac2O = acetic anhydride, 
BzCl = benzoyl chloride, DMF = N,N-dimethylformamide, NaOAc = sodium 
acetate, TBAHS = tetrabutylammonium hydrogen sulfate, Tf2O = 
trifluoromethanesulfonic anhydride. 
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Scheme 3. Synthesis of 4-deoxy-4-fluoro-galactopyranoside 27 and 28. a) 
MOMCl (10.0 equiv), DIPEA (11.0 equiv), CH2Cl2, 40 °C, 18 h, 97%; b) TBAF 
(10.0 equiv), THF, 66 °C, 72 h, 31%, based on 76% purity; c) H2SO4 (10.0 equiv), 
Ac2O (30.0 equiv), rt, 18 h; then NaOAc (20.0 equiv), rt, 0.3 h, 52 % over 2 steps, 
α/β = 3:1; d) HBr/AcOH, CH2Cl2, rt, 1 h; e) methyl 4-hydroxybenzoate (3.0 equiv), 
TBAHS (1.0 equiv), AcOEt/1M Na2CO3 (1:1), rt, 18 h, 40% over 2 steps; f) 2-
thionaphthyl (3.0 equiv), TBAHS (1.0 equiv), AcOEt/1M Na2CO3 (1:1), rt, 18 h, 
69% over 2 steps. Ac2O = acetic anhydride, DIPEA = N,N-diisopropylethylamine, 
MOMCl = chloromethyl methyl ether, NaOAc = sodium acetate, TBAF = 
tetrabutylammonium fluoride, TBAHS = tetrabutylammonium hydrogen sulfate. 
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Scheme 4. Synthesis of 6-deoxy-6-fluoro-galactopyranoside 33 and 34. a) Me-
DAST (1.2 equiv), 2,4,6-collidine (2.4 equiv), CH2Cl2, 80 °C, microwave 
irradiation, 1 h, 87 %; b) AcOH/H2O (4:1), reflux, 18 h; c) Ac2O, pyridine, rt, 72 
h; d) HBr/AcOH, CH2Cl2, rt, 2 h; e) methyl 4-hydroxybenzoate (3.0 equiv), 
TBAHS (1.0 equiv), AcOEt/1M Na2CO3 (1:1), rt, 18 h, 36% over 4 steps; f) 2-
thionaphthyl (3.0 equiv), TBAHS (1.0 equiv), AcOEt/1M Na2CO3 (1:1), rt, 18 h, 
49% over 4 steps. AcOH = acetic acid, Ac2O = acetic anhydride, Me-DAST = 
dimethylaminosulfur trifluoride, TBAHS = tetrabutylammonium hydrogen sulfate. 
In order to increase the molecular diversity of our library, our 
next task focused on the preparation of tetrafluorinated 
galactopyranosides.[14a] Along the way, it became obvious that we 
could also access one trifluorinated galactopyranoside. Hence, 
Scheme 5 described our synthetic endeavours toward this end 
and starts with easily accessible Cerny’s epoxide 35 obtained in 
4 steps from levoglucosan.[28] Nucleophilic fluorination of the 2,3-
anhydro derivative 35 was achieved upon exposure to potassium 
hydrogen fluoride in 73% yield. Treatment of 36 with Deoxo-
Fluor® furnished 2,3-dideoxy-difluoro-glucose 37 in high yield 
with complete retention of configuration. This result can be 
explained by a trans-diaxially positioned benzyloxy group at C-4 
capable of participation through an oxiranium intermediate 
species.[ 29 ] A TiCl4-mediated benzyl deprotection allowed the 
generation of compound 38 in 66% yield, which was the ideal 
precursor to generate the 1,6-anhydro-2,3,4-trideoxy-trifluoro-β-
D-galactopyranose 39. Thus, the free O-4 hydroxyl group on
compound 38 was activated as a triflate and subjected to a
nucleophilic fluorination using TBAF allowing the generation of
compound 39 with complete inversion of configuration. The
isolation and purification of trifluoro 39 proved to be difficult due
to its high volatility. Consequently, the crude mixture was treated
under acidic conditions (H2SO4, Ac2O) generating the acetolysis
product 40 in 63% yield over 3 steps.[30] The configurations of the
fluorine atoms were ascertained based on 19F NMR spectroscopy
(19F NMR (470MHz): 3JF2-H3 = 12.8 Hz, 3JF3-F4 = 13.4 Hz, 3JF3-H4 =
6.4 Hz, 3JF4-H3 = 3JF4-H5 = 27.0 Hz). The aglycones were installed
using the same strategy as before, allowing the preparation of
compounds 42 and 45 via bromide 41. In both reactions, side
product A was isolated from the mixture originating from
elimination of the anomeric bromine (Scheme 5). The last task
was the deoxofluorination at C-6 and represented a more
challenging task than expected.[14a] Upon extensive
experimentation, a DAST-mediated deoxofluorination on 43
allowed the generation of polyfluorohexopyranose 44 in 57% yield
[together with 32% of the L-arabino-hex-5-enopyranoside
derivative B]. For compound 45, due to the instability of the
thionaphthyl moiety under the deoxofluorination conditions,[31] a
different approach was followed. After de-O-acetylation, the free
hydroxyl group of 46 was activated as a triflate and a nucleophilic
fluorination using TBAF gave a disappointing 9% yield. The major
side product of this transformation was the elimination of the C-6
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Scheme 5. Synthesis of trifluorinated 43 and 46 and tetrafluorinated 44 and 47 galactopyranoside derivatives. a) KHF2 (7.0 equiv), ethylene glycol, 200 °C, 2.5 h, 
73%; b) Deoxo-Fluor® (2.0 equiv), THF, microwave irradiation, 100 °C, 1.5 h, 87%; c) TiCl4 (1.1 equiv), CH2Cl2, 0 °C, 0.5 h, 66%; d) Tf2O (2.0 equiv), pyridine (3.0 
equiv), 0 °C, 0.2 h; e) TBAF⋅3H2O (1.5 equiv), CH2Cl2, rt, 15 h; f) Ac2O (30.0 equiv), H2SO4 (10.0 equiv), 0 °C to rt, 18 h, then NaOAc (20.0 equiv), rt, 0.3 h, 63% 
over 3 steps, α/β = 5:1; g) HBr/AcOH, CH2Cl2, rt, 66 h; h) methyl p-hydroxybenzoate (3.0 equiv), TBAHS (1.0 equiv.), EtOAc/ 1M Na2CO3 (1:1), rt, 18 h; 60% over 
2 steps; i) 1M NaOMe, MeOH, rt, 1 h, 99% for 43, 99% for 46; j) DAST (3.0 equiv), CH2Cl2, microwave irradiation, 100 °C, 1 h, 57%; k) 2-thionaphthyl (3.0 equiv), 
TBAHS (1.0 equiv), EtOAc/1M Na2CO3 (1:1), rt, 18 h; 94% over 2 steps; k) Tf2O (2.0 equiv), pyridine (10.0 equiv), 0 °C, 0.5 h; l) 1M TBAF in THF (15 equiv), −78 °C 
to rt, 15 h, 9% over 2 steps. Ac2O = acetic anhydride, DAST = diethylaminosulfurtrifluoride, Deoxo-fluor® = bis(2-methoxyethyl)aminosulfurtrifluoride, TBAF = 
tetrabutylammonium fluoride, TBAHS = tetrabutylammonium hydrogen sulfate, Tf2O = trifluoromethanesulfonic anhydride. 
leaving group leading to derivative C in 83% yield. This example 
clearly shows the limitation of deoxyfluorination with aryl 
thiohexopyranoside analogs. 
The complete deprotection of our target products was 
achieved according to two distinct protocols, depending on the 
substrates (Table 1). In the case of the methyl p-(O-
galactosyl)benzoate analogs, lithium hydroxide was used for 
concomitant de-O-acetylation and generation of the acid moiety, 
allowing preparation of compounds 48, 50, 52, 54, 56, and 57. For 
thiogalactoside analogs, a classical Zemplén de-O-acetylation 
(NaOMe, MeOH) provided the desired analogs 49, 51, 53, and 55. 
Both methods furnished clean products in high yields. 
In order to complement this study, we investigated key 
physical properties of some of our fluorinated carbohydrates. 
Firstly, in order to establish unambiguously the configuration of 
the fluorine atoms of the polyfluorinated galactopyranoside 
derivatives, an X-ray crystallographic analysis of 57 was achieved 
(Figure 2).[32] We obtained a crystalline polymorph with different 
space group than what was previously reported.[14a, 33] In the solid 
state, compound 57 is a dimer and the pyran ring adopts a 4C1 
conformation. Secondly, we compared the 19F NMR spectra of 
compound 48, 50, 52, 54, 56, and 57 (Figure 3). The assessment 
of coupling constants in 19F and 1H NMR represents a reliable tool 
for determination of the absolute configuration and conformation 
of fluorinated carbohydrates. Figure 3 shows that the 
multiplicities are very consistent, and depend on the relative 
spatial relationships between neighbouring atoms. All fluorinated 
carbohydrates adopts the 4C1 conformation. For polyfluorinated 
analogs 56 and 57, a comparison of fluorine signals with their 
monofluorinated counterparts reveals that the F-H coupling 
constants are similar with a slight change in chemical shift. Finally, 
the C-6 fluorine atom in compound 54 adopt either a TG or GT 
conformation. This was confirmed after analysis of the 1H NMR 
spectrum (500 MHz). The proton at C-5 has a chemical shift of 
4.02 ppm with, amongst others, a coupling constant 3JH5-F6 of 15.2 
Hz, corresponding to a gauche conformation with F-6. A similar 
result is obtained for compound 57 (proton at H-5 = 4.52 ppm with 
3JH5-F6 = 12.9 Hz). This result is in opposition with the conformation 
of the fluorine atom at C-6 of compound 57 in the solid state 
(Figure 2). The GG conformer, corresponding to the one from the 
crystal structure, adopts one of the highest energetic 
conformation.[14a, 34] This demonstrates that fluorine NMR are an 
invaluable tool to analyse structural conformation of 
organofluorine compounds. 
Figure 2. X-ray crystallographic analysis derived ORTEP of 57 showing 50% 
thermal ellipsoid probability, carbon (gray), oxygen (red), fluorine (light green), 
hydrogen (white). 
Table 1. Deprotection of acetylated fluorogalactopyranosides generating 
analogs 48−57. 
Entry Starting 
material 
Method[a] Product Yield 
(%)[b] 
1 11 A 89 
2 12 B 97 
3 20 A 92 
4 21 B 98 
5 27 A 86 
6 28 B 94 
7 33 A 93 
8 34 B 98 
9 43 A 94 
10 44 B 97 
[a] Method A: 1M LiOH (10.0 equiv), H2O/MeOH/THF (2:3:5); Method B: NaOMe
in MeOH. 
[b] Yields refer to isolated pure products. 
Figure 3. Direct comparison of 19F resonances of compounds 48, 50, 52, 54, 56, and 57 (19F NMR, 470 MHz). Expansions from the spectrum display coupling 
constant of each signals. 
Antiproliferative activity 
We wished to use our library in various biological systems. 
Consequently, we evaluated the antiproliferative profile of 
fluorinated galactopyranosides. Compounds 43, 46, 48−56 were 
tested for their antiproliferative activity on human HaCaT primary 
epidermal keratinocyte, human HDFn neonatal dermal fibroblast 
and mouse 3T3 embryonic fibroblast normal cells as compared 
with human HT-29 colon adenocarcinoma and human M21 skin 
melanoma cancer cells (Table 2). Most of the fluorinated 
compounds (43 and 48−56) showed no antiproliferative activity 
against normal or cancer cell lines and could therefore be used in 
various cells assays. In contrast, trifluorinated galactose 
derivative 46 with a thionaphthyl moiety presented some activity 
with no selectivity towards normal cell lines (IC50 = 45−69 μM) and 
cancer cell lines (IC50 = 34−38 μM). This is a weak antiproliferative 
agent when compared to Topotecan, a known chimiotherapeutic 
active compound. 
Table 2. Antiproliferative activity (IC50) of molecular probe (48−56) 
derivatives on human HaCaT primary epidermal keratinocyte, human HDFn 
neonatal dermal fibroblast and mouse 3T3 embryonic fibroblast normal cells 
as compared with human HT-29 colon adenocarcinoma and human M21 
skin melanoma cancer cells. 
IC50 (μM)[a] 
Normal cell lines Cancer cell lines 
Compound HaCaT HDFn 3T3 HT-29 M21 
43 > 100 > 100 > 100 > 100 > 100 
46 69 45 56 38 34 
48−56 > 100 > 100 > 100 > 100 > 100 
Topotecan 0.18 0.24 0.48 0.34 2.0 
[a] IC50 is expressed as the concentration of drug inhibiting cell proliferation 
by 50% after 48 h of treatment. 
Biophysical measurements 
Pseudomonas aeruginosa is a Gram-negative bacterium 
and a leading pathogen for infections of immune-compromised 
patients and patients suffering from cystic fibrosis.[35] LecA is a 
virulence factor crucial for biofilm formation by P. aeruginosa and 
has been demonstrated to be involved in adhesion to lung 
tissues.[ 36 ]  This  lectin  has a  strong  specificity  for  α-
galactopyranose terminating oligosaccharides, however β-
galactopyranoside possessing an aromatic aglycon were reported 
to be efficient binders.[15b, 37 ] Moreover, 2-naphthyl-1-thio-β-D-
galactopyranoside were reported to have high affinity with LecA 
(KD of 6.3 μM), an affinity increase nicely supported by the 
available X-ray crystal structure with the lectin (PDB code 
3ZYF).[15b] In the context of this study, we proposed that our library 
of fluorinated galactosides could represent efficient synthetic 
glycomimetics of natural α-linked oligosaccharides with improved 
properties. To unveil such interactions, we first looked at the 
chemical shift perturbations in 1H,15N-TROSY (transverse 
relaxation-optimized spectroscopy) spectra of the backbone 
amide resonances of 15N-labelled LecA introduced by the 
interaction with our fluorinated probes. It is important to note, that 
we performed the first TROSY NMR experiments of LecA and this 
milestone could be useful for future related experiments. 
Complementary to these studies, we followed the perturbation of 
the isolated and sensitive 19F resonances of the compounds. 
Finally, these NMR experiments were corroborated using 
isothermal titration calorimetry experiments. 
The 1H,15N-TROSY- NMR spectrum of 15N-labelled LecA 
clearly demonstrated that the position of the fluorine atom on the 
pyranose ring strongly influence the binding of galactose to the 
protein. This is exemplified in Figure 4a for the spectrum of 2-
deoxy-2-fluoro-galactopyranoside 48 in the presence (orange) 
and absence (blue) of 15N-labelled LecA. Multiple perturbations of 
backbone chemical shifts and line broadening of these 
resonances were visible particularly related to amino acid 
constituting the carbohydrate recognition domain as inferred from 
experiments with unsubstituted galactose. In contrast, 4-deoxy-4-
fluoro-galactopyranoside 52 induces significantly less 
perturbations in the protein backbone indicative for a reduced 
interaction (Figure 4b). Clearly, the fluorine atom at C-4 
abrogates binding to LecA. 
A) 
B) 
Figure 4. Chemical shift perturbations of backbone resonances of LecA upon 
binding to galactose derivatives 48 and 52 using 1H,15N-TROSY NMR 
experiments. Spectra of 350 μM 15N-labelled LecA in the absence (blue) and 
presence (orange) of monofluorinated galactoside are shown for A) 0.2 mM 48 
and B) 1.0 mM 52. Fluorination in C2 (48) induces multiple chemical shift 
perturbation and line broadening while fluorine atom at C-4 (52) abrogates 
binding to LecA. 
Following-up on these results, we thus performed the 
1H,15N-TROSY experiments over all the monofluorinated 
galactosides. The results are shown in Figure 5 and summarize 
the perturbed backbone resonances upon addition of 
monofluorinated  galactopyranosides  48−55.[ 38 ]  Since  no 
assignment backbone resonance is available, labeling of the 
peaks is arbitrary and we utilized these perturbations for 
fingerprinting the interaction patterns. Similar perturbation 
patterns would indicate similar binding patterns. First of all, 
analogs with fluorine atoms at C-3 (50 and 51) and C-4 (52 and 
53) showed limited chemical shift perturbations or changes in
peak intensities, thus suggesting no or weak affinities with LecA.
Hydroxyl group at C-3 and C-4 of galactose are involved in a
coordination to the calcium ion bound to LecA.[39] Consequently,
fluorine atoms at these positions abrogate efficient binding to
LecA. Furthermore, as for compounds with fluorine atom at C-2
(48 and 49) and C-6 (54 and 55), strong change in peak intensity
or chemical shift perturbation were noticed. In fact, the largest
changes were observed for residues involved in the carbohydrate
recognition domain as inferred from galactose binding (Figure 5,
top).[39] Overall, a consensus of perturbed resonances can be
deduced from all compounds suggesting that a common binding
site is shared (Figure 5, bottom).[40]
Thus far, perturbations of the protein resonances were used 
to monitor the interaction. Since, the incorporation of a fluorine 
offers exquisite possibilities in NMR we chose to complement our 
studies and to take advantage of this and perform 19F NMR of 
monofluorinated galactoside derivatives in presence and absence 
of LecA (Figure 6). Changes in peak intensity in the 19F NMR 
spectra were followed as exemplified with 2-deoxy-2-fluoro-
galactopyranoside 48 (Figure 6a). Upon addition of LecA to 48, 
there is a broadening of the peak associated with a reduction of 
the peak intensity by about 40% indicating binding to the lectin. 
All monofluorinated galactopyranosides 48−55 were analysed 
analogously (Figure 6b). Taken together, derivatives with fluorine 
atoms at C-2 (48 and 49) and C-6 (54 and 55) showed large 
changes in peak intensity (35−80%). Also, for these derivatives, 
compounds with the β-S-(2-naphthyl) aglycone (49 and 55) 
experienced largest changes in peak intensity of up to 80%. 
Finally, while no changes in peak intensity could be observed for 
compound 50, significant changes in chemical shift were recorded, 
indicative of a faster exchange rate on the NMR chemical shift 
time scale. 
To evaluate the affinity of the best compounds, we 
performed isothermal titration calorimetry experiments on our 
monofluorinated galactopyranoside analogues (48−49). A typical 
thermogram of LecA interacting with compound 49 is given in 
Figure 7a. First of all, no binding was observed for compounds 
with fluorine atom at position 3 and 4, which are involved in 
coordination of calcium ion. Fluorination at position 2 resulted in 
a slight decrease in affinity. Fluorination at position 6 has a 
stronger effect with decrease of one or two order of magnitude. 
This is in agreement with the role of each hydroxyl group in the 
complex between LecA and galactose (1OKO) (Figure 7b). 
Oxygens at position 3 and 4 are crucial for the interaction, being 
involved in direct coordination of the bridging calcium ion and in 
hydrogen bonds with amino acid side chains. Oxygen O-6 is 
involved in two direct hydrogen bonds with the protein, and 
oxygen O-2 in only one. 
Figure 5. Summary of backbone resonances of LecA perturbed by the presence of monofluorinated galactosides (48-55) and galactose using 1H,15N-TROSY NMR. 
Resonance IDs are arbitrary and cannot be associated with amino acid residues in absence of an assignment, but serve as fingerprints to visualize interaction 
patterns. If the change in peak intensity is more than 20% or if there is a chemical shift perturbation exceeding 0.025 ppm, the residue was attributed a blue color. 
A) B) 
Figure 6. Direct observation of 19F resonances of monofluorinated galactosides 
upon binding to LecA. A) 19F NMR spectrum of compound 48 (blue) and in 
presence of LecA (orange): Reduction of the signal intensity of the galactoside 
indicates binding to LecA. Both spectra were normalized to reference 
trifluoroacetic acid (TFA: −75.6 ppm). B) Percent peak intensity changes of 19F 
monofluorinated galactosides 48−55 in presence of LecA (blue) compared to 
spectra recorded in absence of LecA. Compound 50 was arbitrarily assigned 
with 100% to indicate binding inferred from chemical shift perturbation (orange) 
in absence of intensity reduction. 
It is also of interest to evaluate the effect of fluorination on 
the thermodynamics, by analysing the enthalpy and entropy 
contribution of the 2F-derivative compared to native compounds. 
Fluorination at position 2 decreases strongly the enthalpy 
contribution (loss of 20%) but the entropy barrier is also 
significantly decreased (Table 3). As a result, the decrease in 
affinity is limited, corresponding to a loss of about 10% in free 
energy. The decrease in binding enthalpy can be correlated to the 
loss of the hydrogen bond to Asn107, and the gain in entropy 
contribution to a modification of the water network. Moreover, as 
previously observed, the β-S-(2-naphthyl) aglycone (49 and 55) 
Table 3. Kd values and thermodynamics for the binding LecA to selected 
fluorinated galactopyranoside derivatives and reference compounds in ITC 
assays. Experiments were performed twice and standard deviations was 
lower than 10%. 
Ligand 
−ΔH° 
[KJ mol−1] 
−TΔS° 
[KJ mol−1] 
−ΔG° 
[KJ mol−1] 
Kd
[μM]
α-Gal-O-Me 40.9 16.3 24.6 50.0 
β-Gal-O-Me 19.0 5.3 24.3 55.7 
38.9 11.1 27.8 13.0 β-Gal-O-p-benzoic acid
β-Gal-S-2-thionaphthyl 45.1 14.8 30.3 4.8 
48 31.9 6.9 25.0 41 
49 35.3 8.1 27.2 17 
54[a] - - 20.1 303 
55[a] - - 22.3 124.2 
[a] Due to low affinity, a sigmoid curve could not be obtained for compounds
54 and 55, which precluded the determination of reliable value for ΔH.
provided analogues with higher affinity as compared to their β-O-
benzoic acid counterpart (48 and 54). Futhermore, it is important 
to point out that compound 49 constitute a privilege class of LecA 
inhibitors (3 times more potent than methyl β-D-galactopyranose). 
For one thing, the aromatic thioglycoside represent a stable 
functional group in biological medium by the glycosidically stable 
thio linkage. Also, not only the high C−F bond energy renders 
them resistant to in vivo degradation, fluorine group can increase 
lipophilicity, which in turn can increase cell permeability.[41] Finally, 
in the context of this study, the limitation of our library are the low 
water solubility of polyfluorinated analogues (especially for 
compounds with the β-S-(2-naphthyl aglycone) and the low affinity 
between fluorine atoms with the calcium cation. One can assume 
that our library of fluorinated analogues would be more suitable 
as ligand for other galactophilic proteins that does not bear a 
cationic metal in the carbohydrate recognition domain. 
A) B) 
Figure 7. A) Thermogram of LecA interacting with compound 49. The ITC plot (measure by VP-ITC Microcal) in the lower panel shows the total heat released as a 
function of total ligand concentration for the titration shown in the upper panel. The solid line denotes the best least square fit to experimental data using a one site 
model. B) D-Galactose in the carbohydrate recognition domain of LecA (1OKO).[39] 
The preparation and characterization of the first library of 
fluorinated galactopyranosides was achieved with two aglycones 
at the anomeric position: β-O-benzoic acid and β-S-(2-naphthyl). 
Most of the fluorinated compounds showed no antiproliferative 
activity against normal or cancer cell lines. Also, our library of 
stable glycomimetics can be used as molecular probes with 
galactophilic lectins. The first TROSY NMR following chemical 
shift perturbation of LecA and 19F NMR in presence and absence 
of LecA suggested that analogs with fluorine atoms at C-3 and C-
4 seems to have weak affinities with LecA. Furthermore, 
compounds with fluorine atom at C-2 and C-6 showed strong 
changes in peak intensity or chemical shift perturbations. This 
results was corroborated with isothermal titration calorimetry 
experiments. Compound 49 was a high affinity ligand for LecA 
with dissociation constants of 17 μM. The present investigation 
clearly shows the importance of systematic investigations in the 
search of stable and potent glycomimetics as lectin ligand. By 
blending organic synthesis and biological studies endeavors, we 
strongly believe that the resulting molecules could serve as useful 
tools to deepen investigations on the use of stable glycomimetics 
and to underscore their relevance and their yet underestimated 
potential to medicine. 
Experimental Section 
Chemical synthesis 
All reactions were carried out under an argon atmosphere with dry 
solvents under anhydrous conditions, unless otherwise noted. Dry 
tetrahydrofuran (THF), toluene, benzene, diethyl ether (Et2O), N,N′-
dimethylformamide (DMF), and methylene chloride (CH2Cl2) were 
obtained by passing commercially available pre-dried, oxygen-free 
formulations through activated alumina columns. Yields refer to 
chromatographically and spectroscopically (NMR) homogeneous 
materials, unless otherwise stated. Reagents were purchased at the 
highest commercial quality and used without further purification, unless 
otherwise stated. Reactions were monitored by thin-layer chromatography 
(TLC) carried out on 200 m SiliaPlate™ Aluminium backed TLC (indicator 
F-254) using UV light as visualizing agent and an ethanolic solution of 
phenol and sulphuric acid, and heat as developing agents. SiliaFlash® 
P60 (particle size 40 – 63 m, 230 – 400 mesh) was used for flash column 
chromatography. NMR spectra were recorded on Agilent DD2 (at 500 MHz 
for 1H, 470 MHz for 19F and 126 MHz for 13C) instruments and calibrated 
using residual undeuterated solvent (Chloroform-d: H = 7.26 ppm, C = 
77.16 ppm; DMSO-d6: H = 2.50 ppm, C = 39.52 ppm; Acetone-d6: H = 
2.05 ppm, C = 29.84 ppm; Methanol-d4: H = 3.31 ppm, C = 49.0 ppm)
as an internal reference. Calibration of 19F NMR were done using 
hexafluorobenzene, which have been measured at –162.29 ppm 
compared to the chemical shift of the reference compound CFCl3. The 
following abbreviations were used to designate multiplicities: s = singlet, d 
= doublet, t = triplet, q = quartet, p = quinted, h = sextet, m = multiplet, br 
= broad. Infrared (IR) spectra were recorded on a Thermo Nicolet 380 FT-
IR spectrometer, with ZnSe crystal plate. High-resolution mass spectra 
(HRMS) were recorded on an Agilent serial 1200 TOF (time of flight) 6210 
mass spectrometer using ESI (electrospray ionization). Melting points are 
uncorrected and were recorded on a Stanford Research Systems Optimelt 
MPA100 automated melting point system. Optical rotations were recorded 
on a JASCO DIP-360 digital polarimeter at 589 nm, and are reported in 
units of 10−1 (deg cm2 g−1). 
Cell lines culture 
HaCaT primary epidermal keratinocyte and human HDFn neonatal 
dermal fibroblast human cells were purchased from Thermo Fisher 
Scientific, while mouse 3T3 embryonic fibroblast and human HT-29 colon 
adenocarcinoma cells were purchased from the American Type Culture 
Collection (Manassas, VA). M21 human skin melanoma cells were kindly 
provided by Dr. David Cheresh (University of California, San Diego School 
of Medicine). HaCaT and 3T3 cells were cultured in high-glucose 
Dulbecco’s minimal essential medium (DMEM, Gibco, Thermo Fisher 
Scientific) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco, 
Thermo Fisher Scientific) and 1% antibiotic penicillin-streptomycin (5,000 
U/mL). HDFn cells were cultured in DMEM supplemented with 2% (v/v) 
FBS, 1% penicillin-streptomycin, fibroblast growth factor (3 ng/mL), 
epidermal growth factor (10 ng/mL), hydrocortisone (1 ng/mL) and heparin 
(10 ng/mL). HT-29 and M21 cells were cultured in DMEM supplemented 
with 5% of FBS. Cells were maintained at 37 °C in a moisture-saturated 
atmosphere containing 5% CO2. 
Antiproliferative activity assay 
The growth inhibition potency of all compounds was assessed using 
the procedure recommended by the National Cancer Institute (NCI) 
Developmental Therapeutics Program for its drug screening program with 
slight modifications.[42] Briefly, 96-well Costar microtiter clear plates were 
seeded with 75 L of a suspension of either HaCaT (4.5 × 103), 3T3 (3 × 
103), HDFn (3 × 103), HT-29 (5 × 103), or M21 (3 × 103) cells per well in 
the appropriate medium. Plates were incubated for 24 h. Freshly 
solubilised drugs in DMSO (40 mM) were diluted in fresh medium and 75 
L aliquots containing serially diluted concentrations of the drug were 
added. Final drug concentrations ranged from 100 M to 78 nM. DMSO 
concentration was kept constant at < 0.5% (v/v) to prevent any related 
toxicity. Plates were incubated for 48 h, after which growth was stopped 
by the addition of cold trichloroacetic acid to the wells (10% w/v, final 
concentration). Afterward, plates were incubated at 4 °C for 1 h. Then, 
plates were washed 5-times with distilled water and a sulforhodamine B 
solution (0.1% w/v) in 1% acetic acid was added to each well. After 15 min 
at room temperature, the exceeding dye was removed and was washed 5-
times with a solution of 1% acetic acid. Bound dye was solubilized in 20 
mM Tris base and the absorbance was read using an optimal wavelength 
(530-580 nm) with a SpectraMax® i3x (Molecular Devices). Data obtained 
from treated cells were compared to the control cell plates fixed on the 
treatment day and the percentage of cell growth was thus calculated for 
each drug. The experiments were done at least twice in triplicate. The 
assays were considered valid when the coefficient of variation was < 10% 
for a given set of conditions within the same experiment. 
1H,15N TROSY NMR 
Fluorinated galactopyranosides binding to LecA were validated 
using protein-observed 1H,15N TROSY NMR. All 1H,15N TROSY 
measurements were performed at 310 K in Norell S-3-800-7 3mm tubes 
(Norell) on a Bruker Ascend 700 MHz spectrometer (Bruker, Billerica, MA, 
USA) equipped with a 5mm TCI700 CryoProbeTM.  
Briefly, 1H,15N TROSY spectra of 350 μM (U: 15N) LecA were 
recorded in 20 mM HEPES, 150 mM NaCl, pH 7.4 buffer containing 10 mM 
CaCl2, 100 μM DSS as internal reference and 10% D2O. 0.2-1.5 mM of 
fluorinated D-galactose compound dissolved in DMSO-d6 was added and 
the respective spectrum was compared to a spectrum with the same 
amount (v/v) of DMSO-d6 to factor out changes caused by the solvent. A 
1H, 15N TROSY pulse sequence with WATERGATE solvent suppression, 
128 increments, and 16 scans per increment was applied. Data were 
processed in NMRpipe[43] and further analysed in CCPN.[44]  
1H,15N TROSY resonances were indexed with IDs from 1 to 118 due 
to lack of protein backbone resonance assignment. Based on this 
reference spectrum, resonance IDs were transferred to the spectrum with 
compound in order to compare changes in presence of a compound. In 
case of ambiguities caused by strongly overlapping or disappearing peaks 
among reference spectra, resonance IDs were not transferred. Chemical 
shift perturbation (CSP) were calculated according to: 
 
with i as the difference in chemical shift (in ppm) and  an empirical 
weighing factor of 0.14 for all amino acid backbone resonances.[45] The 
threshold value was set to 0.015 ppm based on four independent 
measurements of reference spectra. In addition to CSPs, peaks that 
reduced at least 20% in normalized signal intensity compared to reference 
spectrum were used as indicators for carbohydrate binding. 
19F NMR measurements 
The measurement using ligand-observed 19F NMR was performed 
to validate binding of fluorinated galactopyranosides to LecA. Briefly, a 
spectrum of 50 μM compound alone and with 100 μM LecA in TBS buffer 
(25 mM Tris, 150 mM NaCl, pH 7.8, 10 mM CaCl2, 100 μM TFA, 10% D2O) 
was recorded at 310 K in Norell S-3-800-7 3mm tubes (Norell) on a Bruker 
Ascend 700 MHz spectrometer (Bruker, Billerica, MA, USA) equipped with 
a 5mm TCI700 CryoProbeTM. All spectra were normalized to internal 
reference TFA at −75.6 ppm and analysed for changes in peak intensity or 
chemical shift. Compounds were defined to bind LecA in 19F NMR 
experiment when changes in peak intensity above 20% or a chemical shift 
of 0.025 ppm occurred in presence of LecA. 
Isothermal titration calorimetry  
Recombinant lyophilized LecA was dissolved in buffer (20 mM 
TRIS-HCl, 100 μM CaCl2, 100 mM NaCl, pH 7.5) and degassed. Protein 
concentration (50 to 300 μM) was checked by measurement of optical 
density by using a theoretical molar extinction coefficient of 28000. 
Galactose derivatives were dissolved directly into the same buffer, 
degassed, and placed in the injection syringe (concentrations varying from 
1.3 to 1.5 mM). ITC was performed using a ITC-200 microcalorimeter 
(MicroCal Inc). LecA was placed into the 200 μM sample cell, at 25 °C. 
Titration was performed with 2 μL injections of carbohydrate ligands every 
120 s. Data were fitted using the “one-site model” using MicroCal Origin 7 
software according to standard procedures. Fitted data yielded the 
stoichiometry (n), the association constant (Ka), and the enthalpy of 
binding ( H). Other thermodynamic parameters (i.e., changes in free 
energy G and entropy S) were calculated from the equation G = H-
T S = −RTlnKa in which T is the absolute temperature and R = 8.314 
J.mol-1.K-1. Two or three independent titrations were performed for each
ligand tested. 
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